A new report from Prophecy Market Insights (PMI) reveals that the cell and gene therapy CDMO market is expected to reach $18.6 billion by 2032.

According to the report, new partnerships with pharmaceutical and biotechnology companies have enabled CDMO players to fuel the rapid growth of capabilities and capacities by helping industries succeed in drug and vaccine production. Integration of clinical trial services is expected to become a new trend for CDMOs as they enter high-value, low-volume segments such as personalized medicine.

Meanwhile, technological advancement in Cell and Gene Therapy has also driven the market’s growth.

Key Highlights:
• In August 2022, Charles River Laboratories International Inc., announced that it had received regulatory approval in the form of GMP (Good Manufacturing Practice) certification for the commercial production of allogeneic cell therapy drug products for distribution in Europe. The company has been awarded a commercial GMP license for a successful EMA inspection of its Memphis CDMO facility.

• In May 2020, WuXi Advanced launched its world-class closed-process CAR-T cell therapy platform. A newly launched platform will enable researchers and biotech companies to accelerate the manufacturing, development, and release of cell and gene therapies for patients.